Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Andecaliximab (DHD06801)

Host species:Chimeric
Isotype:IgG4-kappa
Applications:Research Grade Biosimilar
Expression system:Mammalian Cells
Overview

Catalog No.

DHD06801

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Chimeric

Isotype

IgG4-kappa

Clonality

Monoclonal

Target

Matrix metalloproteinase-9, CLG4B, GELB, 92 kDa type IV collagenase, 92 kDa gelatinase, Gelatinase B, MMP9, MMP-9

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P14780

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

GS-5745, CAS: 1518996-49-0

Clone ID

Andecaliximab

Data Image
  • SDS-PAGE
    SDS PAGE for Andecaliximab
  • Bioactivity
    Detects MMP9 in indirect ELISAs.
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study, PMID: 29691300

Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease, PMID: 29767728

Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study, PMID: 32812320

A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease, PMID: 29846530

Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis, PMID: 29287749

Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1), PMID: 33577358

Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis, PMID: 33052708

Emerging Therapies in the Management of Advanced-Stage Gastric Cancer, PMID: 30271341

Matrix metalloproteinases in the pathogenesis of dengue viral disease: Involvement of immune system and newer therapeutic strategies, PMID: 33634515

Letter: anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 for ulcerative colitis, PMID: 27593425

Failure of MMP-9 Antagonists in IBD: Demonstrating the Importance of Molecular Biology and Well-Controlled Early Phase Studies, PMID: 30010739

Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis, PMID: 27218676

Datasheet

Document Download

Research Grade Andecaliximab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Andecaliximab [DHD06801]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only